Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06251947 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 7, 2024 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2024 to Apr 15, 2024
    • Site details revised at 6 of 6 sites
    v3
  2. Start date: Feb 2024 to Apr 2024v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).
Trial Details
NCT Number NCT06251947
Lead Sponsor Shandong University
Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions
(from sponsor)		 Ovarian Cancer, Cervical Cancer
Related terms Ovarian Neoplasms, Uterine Cervical Neoplasms
Enrollment 83 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov